版本:
中国

BRIEF-Gilead terminates phase 2/3 study of GS-5745 in patients with Ulcerative Colitis

Sept 21 Gilead Sciences Inc :

* 5745 in patients with ulcerative colitis

* A phase 3 study of GS-5745 is ongoing in patients with Gastric Cancer

* DMC recommended that study be terminated early due to meeting pre-specified futility and efficacy criteria

* Decision follows a planned interim analysis of unblinded efficacy and safety data by data monitoring committee

* No safety concerns were noted in this interim analysis.

* Determined there is insufficient evidence of a treatment benefit in group of patients randomized to receive either one of two doses of GS-5745

* Additional phase 2 studies in moderately to severely active crohn's disease, Rheumatoid Arthritis and Cystic Fibrosis is ongoing Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐